Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favorable characteristics of an extended-release profile
Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favorable characteristics of an extended-release profile
May 22, 2023
Previous PostDr Grace Kim, recognised specialist in financial strategy and investor relations in the biopharmaceutical sector
Next PostMedinCell announces the successful pricing of its Global Offering and raises €25 million
